Antiamoebic and toxicity studies of a carbamic acid derivative and its therapeutic effect in a hamster model of hepatic amoebiasis

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 3, 2005, Pages 1160-1168

  Ordaz Pichardo, Cynthia ^a   Shibayama, Mineko ^a   Villa Treviño, Saúl ^a   Arriaga Alba, Myriam ^b   Angeles, Enrique ^c   De La Garza, Mireya ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b HOSPITAL JUÁREZ DE MÉXICO   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOANTHRACENE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CARBAMIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; ETHYL 2 METHYL 5 NITROPHENYLCARBAMATE; ETHYL 2 NITROPHENYLCARBAMATE; ETHYL 3 NITROPHENYLCARBAMATE; ETHYL 4 BENZOYLPHENYLCARBAMATE; ETHYL 4 CHLOROPHENYLCARBAMATE; ETHYL 4 HYDROXYPHENYLCARBAMATE; ETHYL 4 IODOPHENYLCARBAMATE; ETHYL 4 METHYLPHENYLCARBAMATE; ETHYL 4 NITROPHENYLCARBAMATE; ETHYLNITRONITROSOGUANIDINE; FORMAZAN; METHYL 4 CHLOROPHENYLCARBAMATE; METRONIDAZOLE; MITOMYCIN C; NITROIMIDAZOLE; UNCLASSIFIED DRUG;

AMEBIASIS; AMES TEST; AMOEBA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASE MISPAIRING; CONTROLLED STUDY; DRUG ACTIVITY; ELECTRON MICROSCOPY; ENTAMOEBA HISTOLYTICA; ENZYME ACTIVITY; EUKARYOTIC CELL; FRAMESHIFT MUTATION; GENOTOXICITY; LIVER ABSCESS; LIVER AMEBIASIS; LIVER CELL; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; SALMONELLA ENTERICA; TROPHOZOITE; VALIDATION PROCESS;

AMEBICIDES; ANIMALS; CARBAMATES; CRICETINAE; DISEASE MODELS, ANIMAL; ENTAMOEBA HISTOLYTICA; LIVER; LIVER ABSCESS, AMEBIC; MALE; MICROSCOPY, ELECTRON; RATS; RATS, INBRED F344;

EID: 14744271303     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.3.1160-1168.2005     Document Type: Article

References (36)

1. Aguirre-Cruz, M. L., A. Valadez-Salazar, and O. Muñoz. 1990. Sensibilidad in vitro de Entamoeba histolytica a metronidazol. Arch. Investig. Med. 21:23-26.
2. Angeles, E., A. Santillán, I. Martínez, A. Ramírez, and E. Moreno. 1994. A simple method for the synthesis of carbamates. Synth. Commun. 24:2441-2447.
3. Angeles, E., P. Martínez, J. Keller, R. Martínez, M. Rubio, G. Ramírez, R. Castillo, R. López-Castañares, and E. Jiménez. 2000. Ethyl and methylphenylcarbamates as antihelmintic agents: theoretical study for predicting their biological activity by PM3. J. Mol. Struct. (Theor. Chem.) 504:141-170.
4. Ayala, P., J. Samuelson, D. Wirth, and E. Orozco. 1990. Multiresistencia a drogas en Entamoeba histolytica. Arch. Investig. Med. 21:103-107.
5. Cortinas de Nava, C., J. Espinosa, L. Garcia, A. M. Zapata, and E. Martínez. 1983. Mutagenicity of antiamebic and antihelmintic drugs in the Salmonella typhimurium microsomal test system. Mutat. Res. 117:79-91.
6. Diamond, L. S., D. R. Harlow, and C. C. Cunnick. 1978. A new medium for the axenic cultivation of Entamoeba histolytica and other Entamoeba. Trans. R. Soc. Trop. Med. Hyg. 72:431-432.
7. -. Mutat. Res. 188:111-120.
8. Guerrero, M., L. Landa, and D. Rios. 1974. Estudio microscopico de la actividad antiamibiana de nuevos nitroimidazoles. Arch. Investig. Med. 5:403-410.
9. Haque, R., A. S. G. Faruque, P. Hahn, D. M. Lyerly, and W. A. Petri, Jr. 1997. Entamoeba histolytica and Entamoeba dispar infection in children in Bangladesh. J. Infect. Dis. 175:734-736.
10. Hernández-López, H. R., and A. Escobedo-Salinas. 1970. Efectos del metronidazol sobre el absceso hepático amibiano del hamster. Arch. Investig. Med. 1:S125-S128.
11. Knight, R. 1980. The chemotherapy of amoebiasis. J. Antimicrob. Chemother. 6:577-593.
12. Krogstad, D. J., and J. R. Cedeño. 1988. Problems with current therapeutic regimens, p. 741-755. In J. I. Ravdin (ed.), Amebiasis: human infection by Entamoeba histolytica. John Wiley & Sons, Inc., New York, N.Y.
13. Legator, M. S., T. H. Connor, and M. Stoeckel. 1975. Detection of mutagenic activity of metronidazole and niridazole in body fluids of humans and mice. Science 188:1118-1119.
14. León-Félix, J. 1998. Amibiasis experimental: regeneración hepática post-tratamiento antiamibiano. M.Sc. thesis. Centro de Investigación y de Estudios Avanzados del Institute Politécnico Nacional, Mexico City, Mexico.
15. Lowe, C., and B. Maegraith. 1973. Electron microscopy of an axenic strain of Entamoeba histolytica. Ann. Trop. Med. Parasitol. 245:186-187.
16. Maron, D. M., and B. N. Ames. 1983. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 113:173-215.
17. Martínez-Gigena, M. P., M. Shibayama-Salas, V. Tsutsumi, and A. Martínez-Palomo. 1992. Histological changes during healing of experimental amebic liver abscess treated with metronidazole. Arch. Med. Res. 23:209-212.
18. Martínez-Palomo, A., and M. Martínez-Báez. 1983. Selective primary health care: strategies for control of diseases in the developing world. Rev. Infect. Dis. 5:1093-1102.
19. Mendoza-Figueroa, T., R. López-Revilla, and S. Villa-Treviño. 1979. Dose-dependent DNA ruptures induced by the procarcinogen dimethylnitrosamine on primary rat liver cultures. Cancer Res. 39:3254-3257.
20. Mirelman, D., F. De Meester, T. Stolarsky, G. D. Burchard, K. Ernst-Cabrera, and M. Wilchek. 1989. Effects of covalently bound silica-nitroimidazole drug particles on Entamoeba histolytica. J. Infect. Dis. 159:303-309.
21. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63.
22. Neal, R. A. 1978. Antiamoebic activity of drugs given singly and in combination against axenically grown Entamoeba histolytica. Arch. Investig. Med. 9:387-390.
23. Nequiz, M., A. Polo, J. I. Santos-Preciado, and G. B. Vega-Robledo. 2000. Antiamebic activity of the metronidazole-zinc association. Arch. Med. Res. 31:S19-S20.
24. Ordaz-Pichardo, C., M. Shibayama, S. Villa-Treviño, and M. De la Garza. April 2004. Mexico patent PA/a/2004/003417 (Instituto Mexicano de la Propiedad Industrial).
25. Ravdin, J. I. (ed.). 1988. Amebiasis: human infection by Entamoeba histolytica. John Wiley & Sons, Inc., New York, N.Y.
26. Rivera, W. L., H. Tachibana, and H. Kanbara. 1998. Field study on the distribution of Entamoeba histolytica and Entamoeba dispar in the northern Philippines as detected by the polymerase chain reaction. Am. J. Trop. Med. Hyg. 59:916-921.
27. Roe, F. J. 1983. Toxicologic evaluation of metronidazole with particular reference to carcinogenic, mutagenic, and teratogenic potential. Surgery 93:158-164.
28. Samuelson, J. C., A. Burke, and J. M. Courval. 1992. Susceptibility of an emetine-resistant mutant of Entamoeba histolytica to multiple drugs and to channel blockers. Antimicrob. Agents Chemother. 36:2392-2397.
29. Seifert, K., M. Duchene, W. H. Wernsdorfer, H. Kollaritsch, O. Scheiner, G. Wiedermann, T. Hottkowitz, and H. Eibl. 2001. Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica. Antimicrob. Agents Chemother. 45:1505-1510.
30. Shibayania, M., R. Campos-Rodríguez, A. Ramírez-Rosales, L. Flores-Romo, M. Espinosa-Cantellano, A. Martínez-Palomo, and V. Tsutsumi. 1998. Entamoeba histolytica: liver invasion and abscess production by intra-peritoneal inoculation of trophozoites in hamsters, Mesocricetus auratus. Exp. Parasitol. 88:20-27.
31. Trohalaki, S., R. J. Zellmer, R. Pachter, S. M. Hussain, and J. M. Frazier. 2002. Risk assessment to high-energy chemicals by in vitro toxicity screening and quantitative structure-activity relationships. Toxicol. Sci. 68:498-507.
32. Tsutsumi, V., A. Ramírez-Rosales, H. Lanz-Mendoza, M. Shibayama, B. Chávez, E. Rangel-López, and A. Martínez-Palomo. 1992. Entamoeba histolytica: erythrophagocytosis, collagenolysis and liver abscess production as virulence markers. Trans. R. Soc. Trop. Med. Hyg. 86:170-172.
33. Voogd, C. E., J. J. Van der Stel, and J. J. J. A. A. Jacobs. 1974. The mutagenic action of nitroimidazoles. I. Metronidazole, nimorazole, dimetridazole and ronidazole. Mutat. Res. 26:483-490.
34. Walderich, B., A. Weber, and J. Knobloch. 1997. Differentiation of Entamoeba histolytica and Entamoeba dispar from German travelers and residents of endemic areas. Am. J. Trop. Med. Hyg. 57:70-74.
35. Walsh, J. A. 1986. Problems in recognition and diagnosis of amebiasis: estimation of the global magnitude of morbidity and mortality. Rev. Infect. Dis. 8:228-238.
36. World Health Organization, Division of Control of Tropical Diseases. 1998. Life in the 21st century: a vision for all. World Health Organization, Geneva, Switzerland.